Curcumin in the treatment of liver cancer: From mechanisms of action to nanoformulations
Phytotherapy Research · 2023-04 · 37 (4) · 1624-1639
DOI: 10.1002/ptr.7757 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Phytotherapy Research, online erschienen am 08.03.2023. Verfasst von Sulieman Ibraheem Shelash Al-Hawary und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Business Administration, Business School, Al al-Bayt University, Mafraq, Jordan. Hauptthemen laut MEDLINE: Curcumin, Liver Neoplasms. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 155 Literaturangaben. Gefördert von: Scientific Research Deanship at King Khalid University, Abha, Saudi Arabia through the Large Research Group Project.
Abstract (Originalsprache)
Liver cancer is the sixth most prevalent cancer and ranks third in cancer‐related death, after lung and colorectal cancer. Various natural products have been discovered as alternatives to conventional cancer therapy strategies, including radiotherapy, chemotherapy, and surgery. Curcumin (CUR) with antiinflammatory, antioxidant, and antitumor activities has been associated with therapeutic benefits against various cancers. It can regulate multiple signaling pathways, such as PI3K/Akt, Wnt/β‐catenin, JAK/STAT, p53, MAPKs, and NF‐ĸB, which are involved in cancer cell proliferation, metastasis, apoptosis, angiogenesis, and autophagy. Due to its rapid metabolism, poor oral bioavailability, and low solubility in water, CUR application in clinical practices is restricted. To overcome these limitations, nanotechnology‐based delivery systems have been applied to use CUR nanoformulations with added benefits, such as reducing toxicity, improving cellular uptake, and targeting tumor sites. Besides the anticancer activities of CUR in combating various cancers, especially liver cancer, here we focused on the CUR nanoformulations, such as micelles, liposomes, polymeric, metal, and solid lipid nanoparticles, and others, in the treatment of liver cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Business Administration, Business School, Al al-Bayt University, Mafraq, Jordan.
- Medical Laboratory Techniques Department, Al-maarif University College, Al-Anbar-Ramadi, Iraq.
- Medical Laboratory Techniques Department, Al-Farahidi University, Baghdad, Iraq.
- Medical Laboratory Techniques Department, Al-Turath University College, Baghdad, Iraq.
- College of Pharmacy, Al-Ayen University, Nasiriyah, Iraq.
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
ORCID-Profile: Irfan Ahmad, Yasser Fakri Mustafa
Förderung
- Scientific Research Deanship at King Khalid University, Abha, Saudi Arabia through the Large Research Group Project
Zitieren
APA
Shelash Al-Hawary, S. I., Abdalkareem Jasim, S., M Kadhim, M., Jaafar Saadoon, S., Ahmad, I., Romero Parra, R. M., Hasan Hammoodi, S., Abulkassim, R., M Hameed, N., K Alkhafaje, W., Mustafa, Y. F., & Javed Ansari, M. (2023). Curcumin in the treatment of liver cancer: From mechanisms of action to nanoformulations. Phytotherapy Research, 37(4), 1624-1639. https://doi.org/10.1002/ptr.7757
Vancouver
Shelash Al-Hawary SI, Abdalkareem Jasim S, M Kadhim M, Jaafar Saadoon S, Ahmad I, Romero Parra RM, et al. Curcumin in the treatment of liver cancer: From mechanisms of action to nanoformulations. Phytotherapy Research. 2023;37(4):1624-1639. doi:10.1002/ptr.7757
BibTeX
@article{ShelashAlHawary2023,
author = {Shelash Al-Hawary, Sulieman Ibraheem and Abdalkareem Jasim, Saade and M Kadhim, Mustafa and Jaafar Saadoon, Sarah and Ahmad, Irfan and Romero Parra, Rosario Mireya and Hasan Hammoodi, Suzan and Abulkassim, Roua and M Hameed, Noora and K Alkhafaje, Waleed and Mustafa, Yasser Fakri and Javed Ansari, Mohammad},
title = {Curcumin in the treatment of liver cancer: From mechanisms of action to nanoformulations},
journal = {Phytotherapy Research},
year = {2023},
volume = {37},
number = {4},
pages = {1624--1639},
doi = {10.1002/ptr.7757}
}
EUVIMED